Ishibashi F.a,b,c· Suzuki S.a· Nagai M.a· Mochida K.a· Kobayashi K.b· Morishita T.a

Author affiliations

aDepartment of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa-shi, Japan
bKoganei Tsurukame Clinic, Endoscopy Center, Koganei-shi, Japan
cShinjuku Tsurukame Clinic, Digestive Disease Center, Shibuya-ku, Japan

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 02, 2022
Accepted: October 07, 2022
Published online: November 24, 2022

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 4

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Introduction: The purpose of this study was to optimize the surveillance frequency and period for efficient detection of early gastric cancer (EGC) after Helicobacter pylori (HP) eradication. Methods: Data from patients with eradicated HP infection were extracted from the endoscopy databases of two institutions from January 2016 to March 2021. The patients were divided into a close follow-up group with frequent surveillance after eradication and an open follow-up group with an intermittent surveillance method, and the cases of post-eradication EGC found in the two groups were analyzed. Results: Thirty-six out of 9,322 patients (0.39%) in the close follow-up group and 20 out of 11,436 patients (0.17%) in the open follow-up group were found to have EGC. The cumulative incidence of EGC after eradication was significantly higher in the close follow-up group (p = 0.004). The duration between eradication and EGC detection was significantly shorter in the close follow-up group (51.7 vs. 90.5 months, p = 0.002). A logistic regression model revealed that duration after eradication was an independent predictor for detecting EGC in the close follow-up group (p = 0.045). A Cox proportional hazards model revealed that the close follow-up strategy was effective in patients with an eradication duration of less than 65 months to identify EGC (p = 0.015), but there was no difference between the two strategies in patients with an eradication duration of more than 65 months (p = 0.624). Discussion/Conclusions: Frequent surveillance after HP eradication is efficient for the early detection of EGC during the first 65 months.

© 2022 S. Karger AG, Basel

References Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylorion incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008 Aug;372(9636):392–7. Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018 Mar;378(12):1085–95. Nakata R, Nagami Y, Hashimoto A, Sakai T, Ominami M, Fukunaga S, et al. Successful eradication of Helicobacter pylori could prevent metachronous gastric cancer: a propensity matching analysis. Digestion. 2021;102(2):236–45. Watari J, Tomita T, Tozawa K, Oshima T, Fukui H, Miwa H. Preventing metachronous gastric cancer after the endoscopic resection of gastric epithelial neoplasia: roles of Helicobacter pylori eradication and aspirin. Gut Liver. 2020 May;14(3):281–90. Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011 Mar;46(3):318–24. Shiotani A, Haruma K, Graham DY. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol. 2014 Sep;20(33):11552–9. Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016 Oct;84(4):618–24. Toyoshima O, Yamaji Y, Yoshida S, Matsumoto S, Yamashita H, Kanazawa T, et al. Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication. Surg Endosc. 2017 May;31(5):2140–8. Take S, Mizuno M, Ishiki K, Kusumoto C, Imada T, Hamada F, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 Mar;55(3):281–8. Shichijo S, Uedo N, Michida T. Detection of early gastric cancer after Helicobacter pylori eradication. Digestion. 2021;103(1):54–61. Online ahead of print Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013 Nov;8(11):e79088. Hamashima C, Shabana M, Okada K, Okamoto M, Osaki Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015 Dec;106(12):1744–9. Yao K, Uedo N, Kamada T, Hirasawa T, Nagahama T, Yoshinaga S, et al. Guidelines for endoscopic diagnosis of early gastric cancer. Dig Endosc. 2020 Jul;32(5):663–98. ASGE Standards of Practice Committee, Evans JA, Chathadi KV, Chandrasekhara V, Decker GA, Early DS, Fisher DA, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015 Jul;82(1):1–8. Hamashima C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan. Jpn J Clin Oncol. 2018 Mar;48(3):278–86. Sato C, Hirasawa K, Tateishi Y, Ozeki Y, Sawada A, Ikeda R, et al. Clinicopathological features of early gastric cancers arising in Helicobacter pylori uninfected patients. World J Gastroenterol. 2020 May;26(20):2618–31. Nishizawa T, Suzuki H, Arano T, Yoshida S, Yamashita H, Hata K, et al. Characteristics of gastric cancer detected within 1 year after successful eradication of Helicobacter pylori. J Clin Biochem Nutr. 2016 Nov;59(3):226–30. Saka A, Yagi K, Nimura S. Endoscopic and histological features of gastric cancers after successful Helicobacter pylori eradication therapy. Gastric Cancer. 2016 Apr;19(2):524–30. Ishibashi F, Kobayashi K, Fukushima K, Tanaka R, Kawakami T, Kato J, et al. Quality indicators for the detection of Helicobacter pylori-negative early gastric cancer: a retrospective observational study. Clin Endosc. 2020 Nov;53(6):698–704. Park MS, Yoon JY, Chung HS, Lee H, Park JC, Shin SK, et al. Clinicopathologic characteristics of interval gastric cancer in Korea. Gut Liver. 2015 Mar;9(2):166–73. Choi KS, Jun JK, Park EC, Park S, Jung KW, Han MA, et al. Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One. 2012;7(11):e50041. Ishibashi F, Kobayashi K, Kawakami T, Tanaka R, Sugihara K, Baba S. Quality management system for screening esophagogastroduodenoscopy improves detection of Helicobacter pylori-negative interval gastric cancer. Endosc Int Open. 2021;09(12):E1900–8. Pimenta-Melo AR, Monteiro-Soares M, Libanio D, Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1041–9. Japanese Gastric Cancer Association. Japanese classification of gastric Carcinoma. 15th ed. Tokyo: Kanehara Shuppan; 2017. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(03):87–97. R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. URL https://www.R-project.org/. Hamashima C, Ogoshi K, Narisawa R, Kishi T, Kato T, Fujita K, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015 Feb 28;21(8):2460–6. Khalil Q, Gopalswamy N, Agrawal S. Missed esophageal and gastric cancers after esophagogastroduodenoscopy in a midwestern military veteran population. South Med J. 2014;107(4):225–8. Sakitani K, Nishizawa T, Arita M, Yoshida S, Kataoka Y, Ohki D, et al. Early detection of gastric cancer after Helicobacter pylori eradication due to endoscopic surveillance. Helicobacter. 2018 Aug;23(4):e12503. Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007 Apr 1;25(7):805–12. Article / Publication Details

First-Page Preview

Received: August 02, 2022
Accepted: October 07, 2022
Published online: November 24, 2022

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 4

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.